
Opinion|Videos|January 24, 2025
Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg
Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard 8-week dosing, with primary end points assessing noninferiority in visual acuity maintenance.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Aflibercept 8 mg was evaluated in the PULSAR and PHOTON trials for neovascular age-related macular degeneration and diabetic macular edema. Could you briefly review the design of these trials?
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement

















































